Evidence map›Paper›PMID 41535394›Full record

ArticleScientific reports2026

Evaluation of the visual field test algorithm: the Ambient Interactive ZEST-EX (AIZE-EX).

Hiroki Nomoto, Chota Matsumoto, Keiji Yoshikawa, Mami Nanno, Shinji Kimura, Satoshi Inoue, Kenzo Yamanaka, Shunji Kusaka

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hiroki NomotoDepartment of Ophthalmology, Faculty of Medicine, Kindai University, Osaka, Japan. nomoto@med.kindai.ac.jp.
Chota MatsumotoDepartment of Ophthalmology, Faculty of Medicine, Kindai University, Osaka, Japan.
Keiji YoshikawaYoshikawa Eye Clinic, Tokyo, Japan.
Mami NannoKagurazaka Minamino Eye Clinic, Tokyo, Japan.
Shinji KimuraCREWT Medical Systems Inc.,, Tokyo, Japan.
Satoshi InoueCREWT Medical Systems Inc.,, Tokyo, Japan.
Kenzo YamanakaCREWT Medical Systems Inc.,, Tokyo, Japan.
Shunji KusakaDepartment of Ophthalmology, Faculty of Medicine, Kindai University, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ambient Interactive ZEST EX (AIZE-EX) is a newly developed, time-saving visual field (VF) test algorithm for follow-up assessments in glaucoma patients that utilizes prior AIZE results. This study compared VF test results between AIZE and AIZE-EX in patients with glaucoma. Ninety-two eyes from 46 glaucoma patients were examined. All underwent the AIZE test at baseline and both AIZE and AIZE-EX tests at follow-up. Two test patterns were employed: 24-2 (44 eyes) and 24plus(1-2) (48 eyes). Mean deviation (MD), pattern standard deviation (PSD), mean sensitivity (MS), and test duration were compared between visits using the Mann-Whitney U test, and pointwise sensitivity differences were calculated. MD, PSD, and MS values obtained from AIZE-EX showed no significant differences compared with those from baseline and follow-up AIZE tests. Test duration for AIZE remained consistent between visits, whereas AIZE-EX reduced test time by approximately 10-30% (p<0.001). AIZE-EX demonstrated comparable performance to AIZE in detecting glaucomatous VF abnormalities, while significantly reducing test duration. These findings suggest that AIZE-EX may serve as a preferred algorithm for follow-up VF examinations in glaucoma patients.

Indexed as

AlgorithmsGlaucomaVisual FieldsVisual Field TestsAgedFemaleHumansMaleMiddle AgedAIZEAIZE-EXGlaucomaGlaucoma follow-upImo vifaTEMPOTest algorithmVisual field test

Identifiers

PMID41535394
PMCPMC12881587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.